Core Insights - Aurora Innovation highlighted 2025 as a defining year, marking the launch of its first driverless commercial trucking operations on U.S. public roads and significant advancements in its operational domain and commercialization plans [4] Operational Developments - The company initiated supervised autonomous operations on bidirectional lanes between Dallas and Laredo, aiming for driverless validation within the current quarter [1] - Aurora's latest software release expanded driverless operations to handle inclement weather, addressing a limitation that affected operations in Texas about 40% of the time during 2025 [2] - The Aurora Driver surpassed 250,000 driverless miles in January, nearly tripling cumulative miles since early October, maintaining 100% on-time performance and a perfect safety record with zero collisions attributed to the Aurora Driver [3][7] Financial Performance - Aurora reported fourth-quarter 2025 revenue of $1 million, a 25% sequential increase from the third quarter, with total revenue for fiscal 2025 reaching $3 million [18] - The company ended 2025 with nearly $1.5 billion in liquidity and expects average quarterly cash use of $190–220 million in 2026, targeting break-even gross margin by year-end and positive free cash flow by 2028 [5][20][22] Future Projections - For 2026, Aurora guided revenue of $14–16 million, with expectations of more than 200 driverless trucks in operation by year-end, translating to an $80 million run-rate into 2027 [6][21] - The company plans to deploy a new fleet with second-generation "Harbor" hardware, enabling operations without partner-requested observers, and aims to transition to a driver-as-a-service model starting in 2027 [11][13] Partnerships and Technology - Aurora emphasized its vehicle-agnostic approach and multi-OEM strategy, with partnerships including Volvo and PACCAR, and noted progress in integrating its second-generation commercial hardware kit into Volvo trucks [15][16] - The company is advancing a third-generation commercial hardware kit with AUMOVIO, targeting the supply of tens of thousands of trucks [17]

Financial Data and Key Metrics Changes - The company has progressed significantly since its IPO five years ago, moving from no programs in the clinic to three late-stage development programs [3] - The company is on track to file three Biologics License Applications (BLAs) within a 12-month period, starting with the DMD Delzeta program for accelerated approval in the U.S. [4] Business Line Data and Key Metrics Changes - The Delzeta program for DMD has shown a 25% increase in dystrophin levels, rising from a baseline of 7% to 32%, and a decrease in creatine kinase (CK) to near-normal levels [11][12] - The company plans to present functional data for Delzeta ahead of schedule, indicating strong progress in its clinical trials [16] Market Data and Key Metrics Changes - There are approximately 900 boys and young men in the U.S. diagnosed with DMD exon 44, with about 50% of them treated at the same 40 centers of excellence [33] - The company anticipates being the first and best therapy available for DMD patients, leveraging its established patient services and field force [34] Company Strategy and Development Direction - The company is focused on building a foundational commercial infrastructure that can be leveraged across all three drug opportunities [10] - The strategy includes exploring partnerships and M&A opportunities as the company approaches the commercial phase with potential blockbuster drugs [7][9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in executing the upcoming approvals and launches, emphasizing the importance of maintaining focus on their current programs [9] - The company is optimistic about the regulatory landscape, having aligned with the FDA on the requirements for accelerated approval based on dystrophin and CK data [24][26] Other Important Information - The company has initiated a biomarker study for the Delbrax program, which is expected to provide critical data for the accelerated approval pathway [40] - The company is actively working to ensure global trial enrollment for its FSHD program, indicating strong community interest and support [47] Q&A Session Summary Question: What drove the decision to report the data ahead of schedule? - The company aims to exceed expectations and found that the data was ready sooner than anticipated [16] Question: Can you give us a sense of patient number, follow-up time, and functional endpoints? - The upcoming data will involve 17 patients from the Explore 44 trial, with a focus on various functional measures [18][19] Question: Could you talk about the market opportunity for exon 44 and your go-to-market strategy? - The company sees a significant opportunity in the DMD market, with a well-established infrastructure to support patient access [33] Question: Will there be a pre-BLA meeting, and what will be the focus? - A pre-BLA meeting is planned to ensure the submission package meets FDA expectations [43] Question: What is the expectation for the primary endpoint in the Harbor study? - The company is confident in meeting the primary endpoint and is focused on a comprehensive data package for regulatory approval [52]